Formed in 2008, Neovasc Inc. is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace.
Its products include the Tiara™ technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of refractory angina.
To receive Neovasc news updates Register Now
EuroPCR Reducer Symposium
A Proven, Evidence-Based Therapy When Angina Persists?
Wednesday, 22 May, 2019 16:30 – 18:00
Palais des Congrés, Room 243
Disclaimer: Neovasc Reducer is not approved in the U.S.
Grant Thornton LLP